Listing & Compliance Notices

Metal Sky Star Acquisition Corp received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“Warrants will be suspended at the opening of business on April 9, 2025; and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. Pursuant to Nasdaq Listing Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement. Since the Company failed to complete its initial business combination by March 31, 2025, the Company did not comply with IM-5101-2”

Lionsgate Studios Corp. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“April 1, 2025, the Listing Qualifications Staff of The Nasdaq Global Select Market LLC (“Nasdaq”) provided written notice (the “Notice”) to the Company that it was not in compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) (the “Rules”), which require the Company to hold an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end. The Company has until May 16, 2025, which is 45 days from the date of the Notice, to submit a plan to regain compliance and, if Nasdaq accepts the plan, it may grant up to 180 calendar days from the fiscal year end, o”

AMERICAN VANGUARD CORP received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

“April 2, 2025, the Registrant received a notice of noncompliance (the “NYSE Notice”) from the New York Stock Exchange (“NYSE”) noting that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to the delayed filing of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”). The NYSE has informed the Company that it has up to six months from March 31, 2025 to file its Form 10-K to regain compliance. The Company intends to file the Form 10-K in the near future and thereby regain compliance. In the interim, the C”

Peraso Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 4, 2025, Peraso Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock (“Common Stock”) for the 30 consecutive business days ending on April 3, 2025, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days, or until October 1, 2025, in which to regain”

BioCardia, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5550(b)(1)).

“December 31, 2024, it is no longer in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The Company has until May 16, 2025 to provide Nasdaq with a plan to regain compliance with the foregoing listing requirement. If the Company’s plan to regain compliance is accepted, Nasdaq may grant an extension of up to 180 calendar days from April 1, 2025 for the Company to evidence compliance. The Notice has no immediate effect on the listing or trading of the Company’s common stock and the”

STARZ ENTERTAINMENT CORP /CN/ received a nyse deficiency notice notice regarding other (rules 302).

“April 1, 2025, the New York Stock Exchange (the “NYSE”) notified the Company that it was not in compliance with Section 302 of the NYSE’s listing standards (“Section 302”), which requires listed companies to hold an annual shareholders’ meeting during each fiscal year. As previously announced, in connection with the proposed separation of the Company’s Studios and Starz Businesses, the 2024 annual meeting of shareholders of the Company (the “Annual Meeting”) will be held on April 23, 2025. The Company will regain compliance with Section 302 after the completion of the Annual Meeting. Until the”

LiveOne, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 28, 2025, LiveOne, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, based on the closing bid price for the previous 30 consecutive business days, the listing of the Company’s shares of common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”). The letter from Nasdaq has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market. In accordance with Nasda”

Virpax Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 2, 2025, Virpax Pharmaceuticals, Inc. (the “Company”) received a letter from the Nasdaq Hearings Panel (the “Panel”) indicating that the Panel has determined to delist the Company’s securities from The Nasdaq Stock Market LLC (“Nasdaq”) as a result of the Company’s failure to regain compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). Trading in the Company’s common stock on Nasdaq will be suspended effective at the open of business on Friday, April 4, 2025. Nasdaq will complete the delisting by filing a Form 25 Notificati”

Virpax Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 2, 2025, Virpax Pharmaceuticals, Inc. (the “Company”) received a letter from the Nasdaq Hearings Panel (the “Panel”) indicating that the Panel has determined to delist the Company’s securities from The Nasdaq Stock Market LLC (“Nasdaq”) as a result of the Company’s failure to regain compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). Trading in the Company’s common stock on Nasdaq will be suspended effective at the open of business on Friday, April 4, 2025. Nasdaq will complete the delisting by filing a Form 25 Notificati”

Sky Quarry Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 28, 2025, the Company received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the prior 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until September 24, 2025, to regain compliance. The letter states that the Nasdaq staff will”

Marblegate Acquisition Corp. received a nasdaq deficiency notice notice regarding other (rules IM-5101-2).

“November 19, 2024. On December 19, 2024, the Company received a written notice (the “ Decision ”) from Nasdaq that the Panel had granted the Company’s request to continue its listing on Nasdaq until March 31, 2025 (the “ Extended Date ”), provided that the Company complies with certain conditions, including that the Company will have completed its previously announced business combination pursuant to that certain business combination agreement dated as of February 14, 2023 (the “ Business Combination Agreement ”), by and among Marblegate Asset Management, LLC, Marblegate Capital Corporation (“”

Longevity Health Holdings, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5550(b)(2)).

“Nasdaq Capital Market at the hearing scheduled to occur on April 15, 2025 (the “Hearing”) with respect to the Company’s inability to regain compliance with the $35 million minimum market value of listed securities required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). The Determination Letter stated that the Minimum Bid Price Deficiency serves as an additional basis for delisting the Company’s securities from the Nasdaq Capital Market, and that Panel will consider the Minimum Bid Price Deficiency at the Hearing in their decisi”

Gold Flora Corp. received a otc delisting notice notice regarding other.

“April 2, 2025, the Company received a notice from OTC notifying the Company that, as a result of its receivership filing, the Company no longer qualified for quotation on the OTCQB marketplace and that the quotation of the Company’s securities would be transferred to the OTC Pink Market effective as of the open of trading on April 3, 2025.”

TOMI Environmental Solutions, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 28, 2025, TOMI Environmental Solutions, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.01 per share (the “Common Stock”) was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The notification received has no immediate effect on th”

Aptose Biosciences Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 31, 2025, Aptose Biosciences Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not regained compliance with Nasdaq’s minimum stockholder equity requirement in Listing Rule 5550(b)(1), Nasdaq determined to delist the Company’s securities from The Nasdaq Stock Market, effective on April 2, 2025. The Company and board of directors will review all available options, including an appeal to the determination, but will continue to execute its business plan and will seek to list on a U.S. national securities exchange at the ap”

PGIM ETF TRUST received a other deficiency notice notice regarding other.

“March 28, 2025, the compliance staff (the “Staff”) of Cboe BZX Exchange, Inc. (“Cboe”) provided written notice (the “Notice”) to PGIM ETF Trust (the “Trust”) that it is not in compliance with the continued listing standard set forth in Exchange Rule 14.11(l)(4)(B)(i)(c) of Cboe with respect to one of its series, PGIM Jennison Focused Mid-Cap ETF (the “Fund”). Exchange Rule 14.11(l)(4)(B)(i)(c) provides that Cboe will consider suspension of trading and delisting proceedings if, following the initial twelve month period after commencement of trading on the exchange of a series of ETF shares, the”

LQR House Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 2, 2025, the Company believes it is in compliance with the Minimum Equity Requirement as a result of receiving approximately $9,064,022 in net proceeds from the exercise of warrants and ATM sales from January through March 2025, after considering anticipated net losses through April 30, 2025. Nasdaq will monitor the Company’s ongoing compliance with the Minimum Equity Requirement and, if at the time of its next periodic report the Company does not evidence compliance, it may be subject to delisting. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the reg”

ConnectM Technology Solutions, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“March 27, 2025, ConnectM Technology Solutions, Inc. (“ ConnectM ” or the “ Company ”) received written notice from the Listing Qualifications Staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share required for continued listing on Global Market tier of Nasdaq pursuant to Nasdaq Listing Rule 5450(a)(1) (the “ Minimum Bid Price Requirement ”). In accordance with Nasdaq rules, the Company has been provided an initial pe”

Forward Industries, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“April 1, 2025, Forward Industries, Inc. (the “Company”) received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has evidenced compliance with the minimum $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, in accordance with Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”), and otherwise satisfies all other requirements for continued listing on Nasdaq. Accordingly, the previously disclosed listing matter has been resolved and the hearing before the Nasdaq Hearings Panel canceled. As previously disclosed in that C”

Turnstone Biologics Corp. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“rd; Transfer of Listing. As previously reported, on September 27, 2024, Turnstone Biologics Corp. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company no longer met the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) because the closing bid price for the Company’s common stock was less than $1.00 for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company had a 180-calendar day grace period, or until March 26, 2025, to regai”

Perfect Moment Ltd. received a nyse_american compliance regained notice regarding board independence.

“March 26, 2025, Max Gottschalk delivered notice of his resignation from the Compensation Committee of the Board (the “Compensation Committee”) and the Nominating and Corporate Governance Committee (the “Nominating Committee”, together with the Compensation Committee, the “Committees”) of Perfect Moment, Ltd., (the “Company”) effective immediately. Mr. Gottschalk will remain the chairman of the Board of Directors. Mr. Gottschalk’s resignation from the Committees is not the result of a disagreement with the Company on any matter relating to its operations, policies or practices, but instead to e”

TITAN PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 26, 2025, the Company received a notice (the “Notice”) from the Listing Qualifications staff of Nasdaq notifying the Company that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the period ended December 31, 2024 (“2024 10-K”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2,500,000. In its 2024 10-K, the Company reported stockholders’ equity of $2,440,000, and, as a result, does not currently satisfy Nasdaq”

INVO Fertility, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 31, 2025, the Company evidenced a closing bid price of at least $1.00 per share for 10 consecutive business days and, on March 31, 2025, the Staff determined that the Company has regained compliance with the Rule. Accordingly, the Company’s securities are no longer subject to delisting and the listing matter has been closed.”

Nexentis Technologies Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H)).

“March 28, 2025, N2OFF, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), was below $1.00 per share, which is the minimum closing bid price required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Notice”). This Notice has no immediate effect on the listing of the Company’s Common Stock which will con”

MARKETWISE, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).

“March 25, 2025, the Company received a Staff determination letter stating that the Company had not regained compliance with the Bid Price Rule and that the Company’s common stock is subject to delisting from the Nasdaq Global Market. On March 31, 2025, the Company timely submitted a hearing request to appeal the Staff’s determination to a Hearings Panel (the “Panel”). The Company’s hearing request stays the delisting of the Company’s common stock and the filing of the Form 25-NSE pending the Panel’s decision. The Company previously obtained shareholder approval of a reverse stock split of 1-fo”

Wag! Group Co. received a nasdaq delisting notice notice regarding market value (rules 5450(a)(1), 5450(b)(2)(A)).

“March 25, 2025, Wag! Group Co. (the “Company”) received a written notice from the staff (the “Staff”) of the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that 180 calendar days had elapsed from when the Company was notified that the closing bid price for the Company’s common stock listed on the Nasdaq Global Market (the “Global Market”) was below $1.00 and no longer met the minimum bid price requirement for continued listing on the Global Market under Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share (the “Min”

Wag! Group Co. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5450(b)(2)(A)).

“March 25, 2025, Wag! Group Co. (the “Company”) received a written notice from the staff (the “Staff”) of the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that 180 calendar days had elapsed from when the Company was notified that the closing bid price for the Company’s common stock listed on the Nasdaq Global Market (the “Global Market”) was below $1.00 and no longer met the minimum bid price requirement for continued listing on the Global Market under Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share (the “Min”

Gold Flora Corp. received a other delisting notice notice regarding other.

“March 28, 2025, the Company received a letter from Cboe Canada Inc. (“Cboe”) notifying the Company that, in accordance with Section 11.03(1)(a) of the Cboe listing manual (the “Listing Manual”), trading in the Company’s common stock and warrants was suspended as of the start of trading on March 28, 2025. Cboe has also issued a bulletin to that effect. Additionally, on March 28, 2025, the Company’s securities were halted from quotation on the OTCQB marketplace operated by OTC Markets Group, Inc. Pursuant to Section 11.06 of the Listing Manual, if the suspension is not lifted within 150 days, th”

Vestand Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“March 27, 2025, Nasdaq notified the Company that it had regained compliance with Rule 5550(b)(1). As a result, the hearing scheduled for April 1, 2025 has been cancelled and the Company’s securities will continue to be listed and traded on The Nasdaq Stock Market. Forward-Looking Statements This current report contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “poten”

Smart Powerr Corp. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 25, 2025, the Company received a letter (the “Letter”), from Nasdaq approving an extension of an additional 180 calendar days from the date of the Letter, or until September 22, 2025 (the “Additional Compliance Period”) to regain compliance with the Minimum Bid Price Requirement. The Company’s Common Stock will continue to trade under the symbol “CREG.” If at any time during the Additional Compliance Period, the bid price of the Common Stock closes at or above $1.00 per share for a minimum of ten (10) consecutive trading days, Nasdaq will provide the Company with written confirmation of”

BIODESIX INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“March 24, 2025, Biodesix, Inc. (the “Company”) received written notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until September 22”

GoPro, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“March 25, 2025, GoPro, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s Class A Common Stock has been below $1.00 per share for thirty (30) consecutive business days. Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has 180 calendar days to achieve compliance with the minimum bid price requirement. To regain compliance, the minimum bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of ten (10) c”

ArrowMark Financial Corp. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c), 5605(c)(4)).

“March 25, 2025, ArrowMark Financial Corp. (the “Company”) received a letter from Nasdaq in response to the Company’s notification to Nasdaq that Mr. Michael Stolper, who was an independent director and member of the Company’s Audit Committee, had passed away on March 21, 2025. As a result, the Company has only two independent directors serving on its Audit Committee and is not in compliance with Nasdaq’s audit committee composition requirement of three independent directors as set forth in Nasdaq Listing Rule 5605(c). Consistent with Listing Rule 5605(c)(4), Nasdaq has provided the Company a”

Decoy Therapeutics Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 26, 2025, the Company received a letter (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on the financial statements contained in its Form 10-K for the year ended December 31, 2024, the Company no longer complies with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Equity Standard”). In addition, as of March 28, 2025, the Company does not meet the alternative compliance standards relating to”

Prelude Therapeutics Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 27, 2025, Prelude Therapeutics Inc (the “Company”) received a letter (the “Bid Price Notice”) from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Bi”

Acurx Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 25, 2025, Acurx Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less”

Chrome Holding Co. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“March 24, 2025, the Company received a letter (the “Nasdaq Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that, in connection with the Company’s announcement of its filing of the Bankruptcy Petitions, and in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, the Staff has determined to delist the Company’s securities from The Nasdaq Stock Market. As set forth in the Nasdaq Notice, unless the Company timely requests a hearing before a Nasdaq hearings panel (the “panel”), trading of the Company’s”

ESS Tech, Inc. received a nyse noncompliance notice notice regarding market value (rules 802.01B).

“March 24, 2025, ESS Tech, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the New York Stock Exchange (the “ NYSE ”) indicating that the Company is no longer in compliance with NYSE’s continued listing standards set forth in Section 802.01B (the “ Minimum Market Capitalization Standard ”) due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million. As described in the Notice, as of March 21, 2025, the Company’s 30 tradin”

ContextLogic Inc. received a nasdaq delisting notice notice regarding other (rules 5101).

“March 25, 2025, ContextLogic Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Staff believes the Company is a “public shell,” as that term is defined by Nasdaq under Nasdaq Listing Rule 5101, and therefore subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company disagrees with the Staff’s conclusion and plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq at least pending the hearing a”

Thunder Power Holdings, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5555(a)(1)).

“2025, and will continue to trade under the symbol “AIEV.” As previously disclosed, on September 4, 2024, Nasdaq notified the Company that, based upon the closing bid price for the Company’s common stock for the 30 prior consecutive business days, the Company no longer complied Nasdaq Listing Rules 5450(a)(1), which requires the Company’s listed securities to maintain a minimum bid price of $1.00 per share (the “Bid Price Requirement”), and 5450(b)(2)(A), which requires the Company to maintain a minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 (the “Prior MVLS Requirement”). A”

Thunder Power Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“September 4, 2024, Nasdaq notified the Company that, based upon the closing bid price for the Company’s common stock for the 30 prior consecutive business days, the Company no longer complied Nasdaq Listing Rules 5450(a)(1), which requires the Company’s listed securities to maintain a minimum bid price of $1.00 per share (the “Bid Price Requirement”), and 5450(b)(2)(A), which requires the Company to maintain a minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 (the “Prior MVLS Requirement”). As previously disclosed, on March 7, 2025, the Company received written notice from Nasd”

Bancorp, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“March 21, 2025, The Bancorp, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Global Select Market (“Nasdaq”) notifying the Company that because the Company had not yet filed its Annual Report on Form 10-K for the year ended December 31, 2024 (the “Annual Report”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Annual Report was due on Ma”

IRONWOOD PHARMACEUTICALS INC received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“daq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the SEC. The Notice states that the Company has 60 calendar days from the date of the Notice, or until May 20, 2025, to submit a plan to regain compliance with the Rule. If Nas”

Annovis Bio, Inc. received a nyse deficiency notice notice regarding market value (rules 802.01B).

“March 26, 2025, Annovis Bio, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million. As set forth in the Notice, as of March 25, 2025, the 30 trading-day average global market capitalization of the Company was”

Biomea Fusion, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)).

“March 27, 2025, Biomea Fusion, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A) due to the Company having only two members on its audit committee (the “Audit Committee”) of its Board of Directors of the Company (the “Board”) solely due to a vacancy resulting from Michael (Mick) J.M. Hitchcock, Ph.D.’s resignation from the Audit Committee in connection with his appointment as interim Chief Executive Officer of the Company effective March 25, 2025. The Company ha”

Hudson Acquisition I Corp. received a nasdaq noncompliance notice notice regarding market value.

“January 24, 2025 due to HUDA’s failure to timely satisfy the terms of the Panel’s September 27, 2024 decision (the “ Decision ”). Pursuant to the terms of the Decision, amongst other things, HUDA was required to close its initial business combination with an operating entity and the combined entity was required to evidence compliance with the criteria for initial listing on Nasdaq, including the applicable holders requirements, publicly held shares requirements, market value of listed securities requirements and market value of publicly held shares requirements, by January 20, 2025. On January”

Sharplink, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(1)).

“March 21, 2025, SharpLink Gaming, Inc. (“SharpLink” or the “Company”) received notice (the “Notice”) from the Nasdaq Hearings Panel (the “Hearings Panel”) of The Nasdaq Stock Market, LLC (“Nasdaq”) stating that the Hearings Panel has granted the Company’s request for additional time to achieve compliance with Nasdaq’s continued listing rules and demonstrate long-term compliance with the minimum bid price requirement as set forth in Rule 5550(a)(2) (the “Bid Price Rule”), which requires issuers to maintain a minimum bid price of $1.00 per share on the Nasdaq, and with Listing Rule 5550(b)(1), w”

TRIMBLE INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“March 20, 2025, an expected notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, because the Company is delinquent in filing the 2024 Form 10-K, the Company no longer complies with Nasdaq Listing Rule 5250(c)(1) (the “ Listing Rule ”), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the Securities and Exchange Commission. The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Select Market. In accordance with Nasdaq’s listing rules, t”

DBX ETF TRUST received a other deficiency notice notice regarding other.

“March 13, 2025, the staff of the Listing Qualifications Department (the “Staff”) of the Cboe BZX Exchange, Inc. (the “Exchange”) provided written notice (the “Deficiency Notification”) to DBX ETF Trust (the “Trust”) that, based on the Staff’s review of the period between November 22, 2024 and January 24, 2025 (the “Review Period”), it had determined that Xtrackers USD High Yield BB-B ex Financials ETF (the “Fund”) did not meet the beneficial holders requirement set forth in Exchange Rule 14.11(l)(4)(B)(i)(c) (the “Rule”), which states that the Exchange will consider the suspension of trading i”

JUPITER NEUROSCIENCES, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 21, 2025, Jupiter Neurosciences, Inc. (the “Company”) received a letter (the “Notice”) from the Nasdaq Stock Market LLC (the “NASDAQ”) notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing of its common stock on the NASDAQ. Listing Rule 5550(a)(2) requires the registrant to maintain a minimum bid price of $1.00 USD per share for its securities listed on the NASDAQ, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficie”